<DOC>
	<DOCNO>NCT01128803</DOCNO>
	<brief_summary>The secretion tumor cell alpha fetoprotein ( AFP ) observe 50 60 % hepatocellular carcinoma . The AFP use marker tumor recurrence treatment may consider tumor antigen specific hepatocellular carcinoma.The aim project use alpha fetoprotein ( AFP ) tumor antigen propose approach immunotherapy hepatocellular carcinoma base injection autologous dendritic cell load specific peptide AFP .</brief_summary>
	<brief_title>Immunotherapy Hepatocellular Carcinoma Induction Anti-alpha Fetoprotein Response</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Hepatocellular</mesh_term>
	<criteria>Preinclusion Criteria : Adults ( men woman ) age 18 80 year Patients affiliate social security reimbursement system Signed informed consent Hepatocellular carcinoma At least one dosage Alphafoetoprotein â‰¥ 40 ng/ml Patient already treat chemoembolization , percutaneous destruction ( alcohol radiofrequency ) , surgery Sorafenib . Negative test pregnancy effective contraception Patient HIV , Hep B , Hep C , HTLV1 2 , Syphilis HLA A 0201 group Life expectancy &lt; 3 month Pregnancy breastfeed Severe autoimmune disease Another malignant tumor except consider cure since 5 year History uncontrolled psychiatric condition Risk factor Creutzfeldt Jacobs disease Decompensated cirrhosis ( ascites ChildPugh score great 8 ) Hepatic transplantation</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>November 2013</verification_date>
	<keyword>Hepatocellular carcinoma</keyword>
	<keyword>immunotherapy</keyword>
	<keyword>alpha foetoprotein</keyword>
	<keyword>dendritic cell</keyword>
</DOC>